Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot
Health Services Research and Managerial Epidemiology · 01.01.2019 · 6
DOI: 10.1177/2333392819870774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Services Research and Managerial Epidemiology, online erschienen am 15.08.2019. Verfasst von Márió Gajdács und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Since the 1980s, Stenotrophomonas maltophilia has emerged as an important pathogen associated with significant mortality in pneumonia and bacteremia of severely immunocompromised, hospitalized patients. The drug of choice in S maltophilia infections is sulfamethoxazole-trimethoprim (SMX/TMP); SMX/TMP resistance is a serious concern in clinical practice. The aim of this study was to assess the prevalence of S maltophilia in lower respiratory tract (LRTI) samples at a tertiary-care university hospital.
Methods
This retrospective cohort study was carried out using microbiological data collected between January 2008 and December 2017. Routine antimicrobial susceptibility testing was performed for SMX/TMP and levofloxacin; in case of resistance, susceptibility testing for additional antibiotics (tigecycline, amikacin, and colistin) was also performed.
Results
A total of 579 individual S maltophilia isolates were identified (2008-2012: n = 160, 2013-2017: n = 419; P = .0008). In all, 78.46% of patients were younger than 5 or older than 50 years of age and had recent trauma, surgery, or underlying conditions (malignancies, respiratory distress syndrome, congenital disorders, and cystic fibrosis). In 28.16% of samples, more than 1 pathogen was identified, and 5.35% of coisolated pathogens were multidrug resistant (MDR). In all, 12.1% of isolates were SMX/TMP-resistant (2008-2012: 6.12%, 2013-2017: 18.06%; P = .034), while 8.99% were resistant to levofloxacin (2008-2012: 7.86%, 2013-2017: 10.12%; P > .05). SMX/TMP resistance was detected more frequently in samples originating from inpatients (n = 2.50 ± 2.39 vs n = 11.50 ± 3.76; P = .0002).
Conclusions
In all, 5.87% of isolates were extensively drug resistant (XDR), that is, in addition to SMX/TMP, they were resistant to levofloxacin, amikacin, colistin, and tigecycline. The results of our study correspond to the findings in the literature.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary.
- Faculty of Medicine, Institute of Clinical Microbiology, University of Szeged, Szeged, Hungary.
- Faculty of Medicine, Department of Public Health, University of Szeged, Szeged, Hungary.
ORCID-Profile: Márió Gajdács
Zitieren
APA
Gajdács, M., & Urbán, E. (2019). Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot. Health Services Research and Managerial Epidemiology, 6. https://doi.org/10.1177/2333392819870774
Vancouver
Gajdács M, Urbán E. Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot. Health Services Research and Managerial Epidemiology. 2019;6. doi:10.1177/2333392819870774
BibTeX
@article{Gajdcs2019,
author = {Gajdács, Márió and Urbán, Edit},
title = {Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot},
journal = {Health Services Research and Managerial Epidemiology},
year = {2019},
volume = {6},
doi = {10.1177/2333392819870774}
}
EUVIMED